Immune checkpoint inhibitors (pembrolizumab and nivolumab as anti-PD1; atezolizumab as anti-PD-L1; ipilimumab as anti-CTLA4) became a successful strategy to enhance anti-tumor response in many malignancies [68]. This evidence concerns the gene CD274 and neoplasm.